Clinical Trials for H5N1, Bird Flu Vaccine

Published

Specializes in Too many to list.

http://www.earthtimes.org/articles/show/inovio-biomedical-h5n1-avian-influenza,1185434.shtml

Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. (Korean Stock Exchange: 011000) has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio's SynCon™ preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza. Inovio is co-developing VGX-3400 with Korea-based VGX International. The 30-patient three-dose Phase I study will be conducted in multiple clinical research sites in Korea. A parallel study in the U.S. is also planned for this year.

Dr. J. Joseph Kim, Inovio's President and CEO, said, "Initiation of our H5N1 vaccine clinical trial marks an important milestone for our universal flu program. Inovio has been one of the first organizations to demonstrate a vaccine capable of providing protection against a broad set of unmatched influenza sub-types and strains, both seasonal and pandemic, in multiple animal models."

"If we achieve similar results in human studies, this universal vaccine concept has the potential to shift the current reactive paradigm of influenza vaccine design, manufacturing, and delivery. Such a shift would provide tremendous health and economic benefits worldwide," Dr. Kim added

Read more: http://www.earthtimes.org/articles/show/inovio-biomedical-h5n1-avian-influenza,1185434.shtml#ixzz0h1sC2UjZ

Up Vote Up Vote ×
+ Join the Discussion